Thermo Fisher Scientific Adalimumab Monoclonal Antibody (3C2)

Applications

• ELISA (ELISA)

Tested Dilution

• 0.005–0.1 µg/mL

Product Specifications

Additional Formats

• Biotin
• Request custom conjugation

Product Specific Information

Reconstitute the lyophilized antibody with deionized water (or equivalent) to a final concentration of 0.5 mg/mL.

Adalimumab, sold under the trade name Humira among others, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, chronic psoriasis, hidradenitis suppurativa, and juvenile idiopathic arthritis.
Adalimumab is a TNF-inhibiting, anti-inflammatory biologic medication. It binds to tumor necrosis factor-alpha (TNFα), which normally binds to TNFα receptors, leading to the inflammatory response of autoimmune diseases.
By binding to TNFα, adalimumab reduces this inflammatory response. Because TNFα is also part of the immune system, treatment with adalimumab may increase the risk of infections.

Target Information

Adalimumab (Humira) is a humanized monoclonal antibody approved by the U.S. FDA for treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, chronic psoriasis, hidradenitis suppurativa, and juvenile idiopathic arthritis.
Adalimumab binds to TNFα and blocks its interaction with TNFα receptors, reducing the inflammatory response of autoimmune diseases.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.